BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boehringer Ingelheim Corporation Ohio Drug Plant Shut by U.S. on Quality Issues


2/1/2013 8:27:44 AM

Boehringer Ingelheim GmbH, the world’s largest family-owned drugmaker, agreed to stop production at an Ohio plant until it fixes manufacturing practices that led to about 40 product recalls in a decade. U.S. District Judge Lesley Wells in Cleveland today approved a consent decree against Boehringer’s Ben Venue Laboratories plant in Bedford, Ohio, and three company officers after quality assurance rules were violated, leading to particles found in injectable drugs, the Food and Drug Administration said in a statement. Marjorie Moeling, a spokeswoman for the Ingelheim, Germany-based drugmaker, didn’t immediately return a call or an e-mail requesting comment. Drugs produced by Ben Venue have been withdrawn about 40 times since 2002, reflecting “a continuing pattern of significant deviations from current good manufacturing practices,” the U.S. Justice Department said in a statement. Among the medicines was Sanofi’s Fludara leukemia therapy, pulled in February 2012 because it may not have been sterile. “The company’s failure to promptly address these problems put patients at risk of receiving poor quality drugs and compromises the availability of medically necessary products,” Melinda K. Plaisier, acting associate commissioner for regulatory affairs at the FDA, said in the statement. “This company continued to violate the law, and the FDA took action to help ensure that medicines that consumers rely on are safe, effective, and of high quality.”

Read at Bloomberg
Read at News Release
Read at Modern Healthcare

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES